Drug Pharmacologic Class Indication More Information
Endocrine Disorders
Tlando™ (testosterone undecanoate) Androgen For testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. FDA Approves Oral Testosterone Replacement Therapy Tlando
Gastrohepatic Disorders
Rinvoq® (upadacitinib) Janus kinase inhibitor Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to 1 or more TNF blockers. Rinvoq Drug Monograph
Neurologic Disorders
Adlarity® (donepezil transdermal system Acetylcholinesterase inhibitor Treatment of mild, moderate, and severe dementia of the Alzheimer type. Donepezil Transdermal Patch Approved for Alzheimer Disease
Fintepla® (fenfluramine) Oral Solution Sympathomimetic Treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. Fintepla Drug Monograph
Lynparza® (olaparib) Poly (ADP-ribose) polymerase (PARP) inhibitor Adjuvant treatment of patients with deleterious or suspected deleterious germline BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Lynparza Drug Monograph
Opdivo® (nivolumab) Programmed death receptor-1 (PD-1) blocking antibody In combination with platinum-doublet chemotherapy, for neoadjuvant treatment of adult patients with resectable (tumors ≥4cm or node positive) non-small cell lung cancer. Opdivo Drug Monograph
Opdualag (nivolumab and relatlimab-rmbw) PD-1 blocking antibody and lymphocyte activation gene-3 blocking antibody For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag Drug Monograph
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Radioligand therapeutic agent For the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pluvicto Approved for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer